ECSP10010670A - Derivados de azacarbolinas, su preparación y su utilización terapéutica - Google Patents

Derivados de azacarbolinas, su preparación y su utilización terapéutica

Info

Publication number
ECSP10010670A
ECSP10010670A EC2010010670A ECSP10010670A ECSP10010670A EC SP10010670 A ECSP10010670 A EC SP10010670A EC 2010010670 A EC2010010670 A EC 2010010670A EC SP10010670 A ECSP10010670 A EC SP10010670A EC SP10010670 A ECSP10010670 A EC SP10010670A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
branched
heterocycloalkyl
linear
therapeutic use
Prior art date
Application number
EC2010010670A
Other languages
English (en)
Inventor
Neil Moorcroft
Serge Mignani
Christopher Arendt
Didier Babin
Olivier Bedel
Thierry Gouyon
Mikhail Levit
Ronghua Li
David Papin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP10010670A publication Critical patent/ECSP10010670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevas azacarbolinas de fórmula (I), en la que : R3, R4 representan independientemente el uno del otro H; hal; CF3; oxi sustituido; alcoxi opcionalmente sustituido; amino opcionalmente sustituido; carbonilo sustituido; carboxilo opcionalmente sustituido; amida opcionalmente sustituida; azufre tales como sulfuros, sulfóxidos o sulfonas opcionalmente sustituidos; alquilo C1-C10 lineal, ramificado o cíclico que contiene opcionalmente un heteroátomo opcionalmente sustituido; alquenilo C2-C7 lineal, ramificado o cíclico opcionalmente sustituido; alquinilo C2-C6 lineal o ramificado opcionalmente sustituido; arilo o heteroarilo opcionalmente sustituido; heterocicloalquilo opcionalmente sustituido; R6 representa heteroarilo, C(O)NR1aR1b, heterocicloalquilo o -C(O)heterocicloalquilo todos opcionalmente sustituidos; en el estado de base o de sal de adición a un ácido. Utilización en terapéutica para el tratamiento del cáncer y procedimientos de síntesis.
EC2010010670A 2008-06-12 2010-12-03 Derivados de azacarbolinas, su preparación y su utilización terapéutica ECSP10010670A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12

Publications (1)

Publication Number Publication Date
ECSP10010670A true ECSP10010670A (es) 2011-01-31

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010670A ECSP10010670A (es) 2008-06-12 2010-12-03 Derivados de azacarbolinas, su preparación y su utilización terapéutica

Country Status (26)

Country Link
US (1) US20110178053A1 (es)
EP (1) EP2303882A2 (es)
JP (1) JP2011522867A (es)
KR (1) KR20110016998A (es)
CN (1) CN102124007A (es)
AR (1) AR072084A1 (es)
AU (1) AU2009259114B2 (es)
BR (1) BRPI0915204A2 (es)
CA (1) CA2725093A1 (es)
CO (1) CO6280536A2 (es)
CR (1) CR11814A (es)
DO (1) DOP2010000366A (es)
EA (1) EA018945B1 (es)
EC (1) ECSP10010670A (es)
IL (1) IL209840A0 (es)
MA (1) MA32460B1 (es)
MX (1) MX2010013699A (es)
NI (1) NI201000210A (es)
NZ (1) NZ589839A (es)
PE (1) PE20110122A1 (es)
SV (1) SV2010003754A (es)
TW (1) TW201002711A (es)
UA (1) UA101668C2 (es)
UY (1) UY31895A (es)
WO (1) WO2009150381A2 (es)
ZA (1) ZA201008387B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151598A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
CN102118969B (zh) 2008-06-12 2017-03-08 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
CN102365282A (zh) * 2009-03-24 2012-02-29 赛诺菲 9H-吡咯并[2，3-b：5，4-c’]二吡啶氮杂咔啉衍生物、其制备方法及其治疗用途
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
KR102700664B1 (ko) * 2017-08-07 2024-08-29 조인트 스탁 컴퍼니 “바이오케드” Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2009151598A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use

Also Published As

Publication number Publication date
BRPI0915204A2 (pt) 2019-01-15
EA018945B1 (ru) 2013-11-29
KR20110016998A (ko) 2011-02-18
PE20110122A1 (es) 2011-03-07
CR11814A (es) 2011-01-10
WO2009150381A2 (fr) 2009-12-17
CN102124007A (zh) 2011-07-13
NI201000210A (es) 2011-05-09
TW201002711A (en) 2010-01-16
UA101668C2 (ru) 2013-04-25
MA32460B1 (fr) 2011-07-03
WO2009150381A3 (fr) 2010-02-18
JP2011522867A (ja) 2011-08-04
EA201170002A1 (ru) 2011-08-30
MX2010013699A (es) 2011-02-23
CO6280536A2 (es) 2011-05-20
AU2009259114A1 (en) 2009-12-17
ZA201008387B (en) 2012-02-29
EP2303882A2 (fr) 2011-04-06
IL209840A0 (en) 2011-02-28
US20110178053A1 (en) 2011-07-21
AR072084A1 (es) 2010-08-04
CA2725093A1 (fr) 2009-12-17
DOP2010000366A (es) 2010-12-31
AU2009259114B2 (en) 2013-05-23
UY31895A (es) 2010-01-29
SV2010003754A (es) 2011-03-15
NZ589839A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
ECSP10010670A (es) Derivados de azacarbolinas, su preparación y su utilización terapéutica
AR098343A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112014025564A2 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
BR112014015363A8 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
AR087655A1 (es) Sulfoxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
SV2011004063A (es) Moduladores de gpr 119
AR085195A1 (es) Metodo de tratamiento de cancer
PE20091843A1 (es) Inhibidores de catepsina c
GT201500334A (es) Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
UY31065A1 (es) Heterociclos ciclicos
PE20150289A1 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
NI201400021A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
AR094921A1 (es) Derivados de 2-acilaminotiazol o su sal
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112015004523A2 (pt) compostos de tetraciclina
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
AR112353A1 (es) Compuesto de insulina acilada
AR109467A1 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño